Elevation Oncology (ELEV) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

ELEV Elevation Oncology

Watchlist

0.605
+0.024+4.15%

Close Nov 21 16:00 ET

0.610
+0.005+0.79%

Pre 07:18 ET

35.78MMarket Cap-756P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | Elevation Oncology Inc : Wedbush Cuts Target Price to $5 From $8
ReutersNov 7 08:33 ET
Elevation Oncology's Promising Progress and Potential: Buy Rating Justified by Advancements in Gastric Cancer Treatment and Strong Financial Outlook
TipRanksNov 7 00:36 ET · Ratings
Elevation Oncology's Q3 2024 Highlights and Financial Report
TipRanksNov 6 23:28 ET
TD Cowen Maintains Elevation Oncology(ELEV.US) With Buy Rating
Moomoo NewsNov 6 16:32 ET · Ratings
TD Cowen Sticks to Its Buy Rating for Elevation Oncology (ELEV)
TipRanksNov 6 16:15 ET · Ratings
Elevation Oncology | 8-K: Elevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Achievements
SECNov 6 07:47 ET

Comments

porsh

Oct 22 13:01

$Elevation Oncology (ELEV.US)$ when will you squeeze

Jaguar8

Sep 23 06:30

NEWS

$Elevation Oncology (ELEV.US)$
Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2

Boxman

Aug 8 20:59

Doing pretty good

$Elevation Oncology (ELEV.US)$ Second Quarter 2024 Financial Results
As of June 30, 2024, Elevation Oncology had cash, cash equivalents and marketable securities totaling $110.8 million, compared to $83.1 million as of December 31, 2023. The increase in cash reflects net proceeds of $44.2 million, which Elevation Oncology raised through its at-the-market (ATM) facility in the first half of 2024, partially offset by cash used to fund operating activities